First close · Healthtech
Unravel Health closes more than £2m for home hormone testing
The first close will support validation studies and preparations for early-access devices in 2027.
Unravel Health completed a first close of more than £2 million on October 14 within a £2.5 million financing round. Final investors were expected to join in the following weeks.
Conduit EIS Impact Fund and Wrightwood led the round, joined by Leo Capital, Embryo Ventures, HERmesa and Zinc. The London company will use the money for external equivalency studies, additional biomarkers and regulatory work.
Use of funds
External equivalency studies
Additional biomarkers
Regulatory approval work
Funding history
First close · This round>£2M